We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.4%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$970M
AUM Growth
-$80.8M
Cap. Flow
+$24.5M
Cap. Flow %
2.53%
Top 10 Hldgs %
34.67%
Holding
117
New
17
Increased
44
Reduced
27
Closed
27

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$35.1M
2
PTCT icon
PTC Therapeutics
PTCT
+$19.2M
3
NVST icon
Envista
NVST
+$18.5M
4
SYK icon
Stryker
SYK
+$17.7M
5
ABBV icon
AbbVie
ABBV
+$16.6M

Top Sells

Rank Stock Value
1
MASI
Masimo
MASI
+$26M
2
TERN
Terns Pharmaceuticals
TERN
+$25.1M
3
FOLD
Amicus Therapeutics
FOLD
+$21.2M
4
MCK icon
McKesson
MCK
+$21.1M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABSI icon
51
Absci
ABSI
$1.3B
$5.59M 0.58%
1,864,806
+406,154
+28% +$1.18M
TNGX icon
52
Tango Therapeutics
TNGX
$4.43B
$5.57M 0.57%
+266,127
New +$3.7M
MRNA icon
53
PUT
Moderna
MRNA
$22B
$5.08M 0.52%
+100,000
New +$4.67M
CDNA icon
54
CareDx
CDNA
$1.89B
$5.06M 0.52%
291,378
+15,224
+6% +$288K
URGN icon
55
UroGen Pharma
URGN
$2.02B
$4.94M 0.51%
275,000
+106,232
+63% +$2.13M
RARE icon
56
Ultragenyx Pharmaceutical
RARE
$2.67B
$4.92M 0.51%
235,000
+172,970
+279% +$3.9M
FDMT icon
57
4D Molecular Therapeutics
FDMT
$542M
$4.87M 0.5%
522,577
+19,146
+4% +$167K
IRTC icon
58
iRhythm Holdings
IRTC
$3.7B
$4.74M 0.49%
+40,125
New +$5.79M
MMED
59
MiniMed Group Inc
MMED
$4.92B
$4.73M 0.49%
+317,324
New +$5.23M
SIBN icon
60
SI-BONE Inc
SIBN
$757M
$4.72M 0.49%
373,553
-829
-0.2% -$13K
CARL
61
Carlsmed
CARL
$313M
$4.72M 0.49%
+521,123
New +$6.3M
OPRX icon
62
OptimizeRx
OPRX
$120M
$4.58M 0.47%
729,369
+190,720
+35% +$1.77M
VIR icon
63
Vir Biotechnology
VIR
$1.5B
$4.48M 0.46%
+500,000
New +$3.98M
SUPN icon
64
Supernus Pharmaceuticals
SUPN
$2.76B
$4.4M 0.45%
+85,062
New +$4.33M
CAI
65
Caris Life Sciences
CAI
$4.39B
$4.11M 0.42%
229,912
+104,912
+84% +$2.29M
CVRX icon
66
CVRx
CVRX
$127M
$4.06M 0.42%
429,507
+16,489
+4% +$121K
NSPR icon
67
InspireMD
NSPR
$31.9M
$3.94M 0.41%
2,416,518
– –
COGT icon
68
Cogent Biosciences
COGT
$6.91B
$3.85M 0.4%
+100,126
New +$3.7M
AMRX icon
69
Amneal Pharmaceuticals
AMRX
$5.74B
$3.74M 0.39%
+300,752
New +$4.04M
ANNX icon
70
Annexon
ANNX
$878M
$3.73M 0.39%
674,013
+72,811
+12% +$410K
ALGN icon
71
Align Technology
ALGN
$12.1B
$3.64M 0.38%
21,233
-4,052
-16% -$710K
QURE icon
72
uniQure
QURE
$2.67B
$3.38M 0.35%
206,842
-50,540
-20% -$1.02M
WGS icon
73
GeneDx Holdings
WGS
$1.8B
$3.26M 0.34%
50,778
+11,506
+29% +$1.05M
VCYT icon
74
Veracyte
VCYT
$4.44B
$3.26M 0.34%
101,237
+968
+1% +$35.8K
CSTL icon
75
Castle Biosciences
CSTL
$737M
$3.1M 0.32%
126,150
-24,408
-16% -$799K
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GLR
Great Lakes Retirement Sandusky, Ohio $967M AUM 25.11% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Parkman Healthcare Partners held 117 positions worth $970M, down 7.7% from $1.05B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners's Q1 2026 filing shows 17 new, 44 increased, 27 reduced and 27 closed positions. Its largest new stake was Eli Lilly: 34,616 shares worth $31.8M. The largest sale was Masimo, an estimated $26M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Parkman Healthcare Partners's largest Q1 2026 buy was Eli Lilly: 34,616 shares worth $31.8M.
  • Parkman Healthcare Partners added most to PTC Therapeutics in Q1 2026, an estimated $19.2M increase.
  • Parkman Healthcare Partners's biggest Q1 2026 reduction was McKesson, cutting an estimated $21.1M.
  • Parkman Healthcare Partners fully exited Masimo in Q1 2026, selling an estimated $26M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $970M portfolio in Q1 2026.
  • Parkman Healthcare Partners opened 17 new positions and closed 27 in Q1 2026.
  • Parkman Healthcare Partners's portfolio value fell 7.7% quarter-over-quarter to $970M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.